OBSOLETE: Holoacardius amorphus

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2161
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Holoacardius amorphus (also known as acardiac amorphous twin) is an extremely rare condition that occurs in monochorionic twin pregnancies, representing the most severe form of the twin reversed arterial perfusion (TRAP) sequence. In this condition, one twin (the 'acardiac' or 'parasitic' twin) fails to develop a functioning heart and lacks recognizable body structures, appearing as an amorphous mass of tissue that may contain skin, connective tissue, bone fragments, cartilage, and occasionally rudimentary organs. This acardiac mass receives its blood supply from the normal ('pump') twin through abnormal arterial-arterial and venous-venous placental anastomoses, with blood flowing in a reversed direction. The primary clinical concern is the impact on the pump twin, whose heart must supply blood to both itself and the acardiac mass. This increased cardiac demand can lead to high-output cardiac failure, polyhydramnios (excess amniotic fluid), hydrops fetalis, preterm delivery, and potentially death of the pump twin. The condition is noted as 'OBSOLETE' in the Orphanet classification (code 2161), likely because it has been reclassified under the broader category of TRAP sequence or acardiac twinning. Management focuses on protecting the pump twin. Treatment options include expectant monitoring with serial ultrasound and echocardiography, and in cases where the pump twin shows signs of cardiac compromise, interventional procedures such as radiofrequency ablation, laser coagulation, or bipolar cord coagulation of the blood supply to the acardiac mass may be performed in utero. Early prenatal diagnosis through ultrasound is essential for appropriate management planning. No ICD-10 code is specifically assigned to this entity.

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Holoacardius amorphus.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Holoacardius amorphus at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Holoacardius amorphus community →

No specialists are currently listed for OBSOLETE: Holoacardius amorphus.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Holoacardius amorphus.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Holoacardius amorphusForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Holoacardius amorphus.

Start the conversation →

Latest news about OBSOLETE: Holoacardius amorphus

No recent news articles for OBSOLETE: Holoacardius amorphus.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about OBSOLETE: Holoacardius amorphus

What is OBSOLETE: Holoacardius amorphus?

Holoacardius amorphus (also known as acardiac amorphous twin) is an extremely rare condition that occurs in monochorionic twin pregnancies, representing the most severe form of the twin reversed arterial perfusion (TRAP) sequence. In this condition, one twin (the 'acardiac' or 'parasitic' twin) fails to develop a functioning heart and lacks recognizable body structures, appearing as an amorphous mass of tissue that may contain skin, connective tissue, bone fragments, cartilage, and occasionally rudimentary organs. This acardiac mass receives its blood supply from the normal ('pump') twin throu

How is OBSOLETE: Holoacardius amorphus inherited?

OBSOLETE: Holoacardius amorphus follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Holoacardius amorphus typically begin?

Typical onset of OBSOLETE: Holoacardius amorphus is neonatal. Age of onset can vary across affected individuals.